povidone-iodine and Virus-Diseases

To better inform medical practitioners on the role of antiseptics in oropharyngeal health and disease, this article focuses on povidone-iodine (PVP-I), an established and widely-available antiseptic agent.. Review of the anti-infective profile, efficacy and safety of PVP-I in managing common upper respiratory tract infections such as the common cold, influenza and tonsillo-pharyngitis, as well as oral complications resulting from cancer treatment (oral mucositis), and dental conditions (periodontitis, caries).. Antiseptics with broad-spectrum anti-infective activity and low resistance potential offer an attractive option in both infection control and prevention. While there is some evidence of benefit of antiseptics in a variety of clinical settings that include dental and oral hygiene, dermatology, oncology, and pulmonology, there appears to be discordance between the evidence-base and practice. This is especially apparent in the management and prevention of oropharyngeal infections, for which the use of antiseptics varies considerably between clinical practices, and is in marked contrast to their dermal application, where they are extensively used as both a prophylaxis and a treatment of skin and wound infections, thus minimising the use of antibiotics.. The link between oral and oropharyngeal health status and susceptibility to infection has long been recognised. The high rates of antibiotic misuse and subsequent development of bacterial resistance (e.g. increasing vancomycin-resistant enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA)) in large parts of the world, especially across Asia Pacific, highlight the need for identifying alternative antimicrobials that would minimise the use of these medications. This, together with recent large-scale outbreaks of, for example, avian and swine influenza virus, further underline the importance of an increasing armamentarium for infection prevention and control.

Topics: Anti-Infective Agents, Local; Bacteria; Bacterial Infections; Humans; Infection Control; Mouth Diseases; Mycoses; Povidone-Iodine; Respiratory Tract Infections; Virus Diseases

Topics: Anti-Infective Agents, Local; COVID-19; Delivery of Health Care; Humans; Povidone-Iodine; SARS-CoV-2; Virus Diseases

Topics: Anti-Infective Agents, Local; Bacterial Infections; Gloves, Surgical; Humans; Needlestick Injuries; Perioperative Care; Povidone-Iodine; Virus Diseases

The use of povidone-iodine (PVP-I) is well known in clinical medical practice. In vitro studies of cell cultures infected by HIV and H5N1 virus have shown that PVP-I has an antiviral action, while the cell hosts were not affected and survived. It is therefore worth investigating whether PVP-I, diluted with Ringer's solution, may have a therapeutic effect by parenteral administration. Specifically, the question is whether small concentrations of intravenous PVP-I could be well tolerated by the human organism, and in addition, if it would be possible to detect a beneficial activity. Its intravenous use may have a potential value against infections (by microbes, viruses, fungi and parasites), as well as an anti-inflammatory activity, especially in cases where antibiotics are ineffective. It could be used as a blood disinfectant, for treating burns, for the prevention of cancer, for the therapy of H5N1 influenza after its mutation, and other potential applications.

Topics: Antiviral Agents; Humans; Injections, Intravenous; Isotonic Solutions; Povidone-Iodine; Ringer's Solution; Virus Diseases

Topics: Bacterial Infections; Conjunctival Diseases; Corneal Diseases; Humans; Keratoconjunctivitis; Mycoses; Ophthalmic Solutions; Povidone; Povidone-Iodine; Virus Diseases